Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma

Purpose We aimed to investigate the recommended dose for the combination of TSU-68, a multiple-receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2 and platelet-derived growth factor receptor-β, and S-1, an oral fluoropyrimidine, in patients with advanced hepato...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ikeda, Masafumi, Shiina, Shuichiro, Nakachi, Kohei, Mitsunaga, Shuichi, Shimizu, Satoshi, Kojima, Yasushi, Ueno, Hideki, Morizane, Chigusa, Kondo, Shunsuke, Sakamoto, Yasunari, Asaoka, Yoshinari, Tateishi, Ryosuke, Koike, Kazuhiko, Arioka, Hitoshi, Okusaka, Takuji
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2014
Matèries:
Phase I Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4169869/
https://ncbi.nlm.nih.gov/pubmed/24829073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0109-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars